Preclinical glioma studies using rGBM mouse models have demonstrated that CD206+ macrophages can remain for extended periods in the tumor microenvironment and sustain a protumorigenic phenotype (according to decreased co-labeling of MHC-II), which may facilitate tumor recurrence and aggressiveness [76,77]. The gene discussed is MRC1; the disease is neoplasm.